<DOC>
	<DOCNO>NCT00979251</DOCNO>
	<brief_summary>This Phase 2 , open label , randomize study investigate virologic benefit , clinical efficacy , safety , tolerability amantadine ribavirin oseltamivir ( TCAD ) versus oseltamivir monotherapy treatment strain influenza A immunocompromised adult pediatric subject .</brief_summary>
	<brief_title>Oral Triple Combination Antiviral Drug Therapy Treatment Influenza A Immunocompromised Subjects</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Oseltamivir</mesh_term>
	<mesh_term>Amantadine</mesh_term>
	<criteria>Confirmed influenza A rapid antigen test Immunocompromised defined recent solid organ hematopoietic transplant , chronic graft vs. host disease , take least 2 immunosuppressant , undergo chemotherapy , take high dose chemotherapeutics , HIV positive Clinical diagnosis influenza Onset illness within 5 day Male female subject agree contraception 24 week last dose Received 1 dose antiviral agent Critically ill Creatinine clearance le 80 mg/mL Females pregnant male whose female partner pregnant Received live attenuate virus vaccine within 3 week</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Influenza</keyword>
	<keyword>Immunocompromised</keyword>
	<keyword>HIV</keyword>
	<keyword>History transplant</keyword>
</DOC>